Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Rahul V, Parghane"'
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 44:314-321
We in this article have presented a review of the guideline recommendations on theranostic positron emission tomography-computed tomography (PET-CT) imaging which will be helpful to assist practitioners in providing appropriate patient care. Multiple
Publikováno v:
The Prostate. 81:1225-1234
Objective The aim of present study was to determine and compare the overall response rates, progression-free survival (PFS), overall survival (OS), and clinical toxicity of the combination of 177Lu-PSMA-617 radioligand therapy (PRLT) and abiraterone
Autor:
Rahul V Parghane, Sandip Basu
Publikováno v:
World Journal of Nuclear Medicine, Vol 20, Iss 3, Pp 312-315 (2021)
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine
A patient of differentiated follicular thyroid carcinoma with unusual sites of metastases is illustrated with 131I and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging findings. The described case harbo
Autor:
Sharmila Banerjee, Arpit Mitra, Megha Tawate, Trupti Upadhye, Sudip Sahoo, Sangita Lad, Sujay Gaikwad, Rahul V. Parghane, Poonam Jagesia, Avik Chakraborty, Sreeja Menon, P.S. Dhami, Sandip Basu
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 36:143-159
Introduction: The quality control parameters of in-house-produced 90Y-Acetate from high-level liquid waste (HLLW) using supported liquid membrane (SLM) technology were validated and compared with t...
Autor:
Sanjay Talole, Manish S. Bhandare, Sandip Basu, Rahul V Parghane, Vikram Chaudhari, Vikas Ostwal, Anant Ramaswamy, Shailesh V. Shrikhande
Publikováno v:
Journal of Nuclear Medicine. 62:1558-1563
OBJECTIVE: The aim of the study was to assess 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in neoadjuvant setting in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In addition, we also evaluated the variables associated with
Publikováno v:
Annals of Nuclear Medicine. 35:92-101
The primary aim of this study was to evaluate the long-term outcome of 177Lu-DOTATATE PRRT in terms of clinical, biochemical and imaging response rates, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in 131I-me
Publikováno v:
6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts.
Autor:
Arpit Mitra, Sandip Basu, Sutapa Rakshit, Sharmila Banerjee, Rahul V Parghane, Trupti Upadhye Bannore
Publikováno v:
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine, Vol 20, Iss 1, Pp 73-81 (2021)
World Journal of Nuclear Medicine, Vol 20, Iss 1, Pp 73-81 (2021)
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy
Autor:
Sanjay Talole, Rahul V Parghane, Sandip Basu, Vikram Chaudhari, Anant Ramaswamy, Manish S. Bhandare, Shailesh V. Shrikhande, Vikas Ostwal
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:913-923
The primary aims of this study were to evaluate the long-term outcome of a “sandwich chemo-PRRT (SCPRRT)” regimen with regard to therapeutic response rate, progression-free survival (PFS), and overall survival (OS) rates in metastatic neuroendocr
Publikováno v:
Seminars in Nuclear Medicine. 50:447-464
Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important modality in the therapeutic armamentarium of advanced, metastatic or inoperable, progressive Neuroendocrine Neoplasms (NENs). This review deliberates on the bas